戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 fluid and may mediate non-thrombotic and non-vasculitic abnormalities of the central nervous system.
2 s the first published report of simultaneous vasculitic and polyarticular manifestations in a patient
3 oteinuria (>/=0.5 gm/24 hours); BILAG renal, vasculitic, and hematologic scores; elevated C-reactive
4 Ab) to CD4 ameliorates the autoimmune renal, vasculitic, and intraocular inflammatory lesions in MRL/
5 tion that manifests with protean infectious, vasculitic, and neuroinflammatory symptoms.
6 ptomic studies of immune cell populations in vasculitic arteries identified a CD4(+) T cell populatio
7                                              Vasculitic arteries were examined for gene expression (r
8                       The particular role of vasculitic, as opposed to synovial or internal organ inf
9 ients there was no evidence of an underlying vasculitic cause for the PUK.
10                                 Furthermore, vasculitic changes can lead renal artery narrowness and
11  in Churg-Strauss syndrome suggests that the vasculitic component of this syndrome may be induced by
12 g often is associated with regression of the vasculitic condition.
13 tis and constitute a substantial subgroup of vasculitic conditions associated with a 'probable aetiol
14  promise for ameliorating systemic lupus and vasculitic conditions, perhaps with reduced toxicity com
15               In giant cell arteritis (GCA), vasculitic damage of the aorta and its branches is combi
16 n pregnancy, the effects of the pregnancy on vasculitic disease activity, and the impact of medicatio
17  immunoglobulin support, with improvement in vasculitic disease and proinflammatory markers.
18 resentation and natural history of a complex vasculitic disease.
19 afety and efficacy of biologic agents in the vasculitic diseases are being increasingly investigated.
20 tis patients, including connective tissue or vasculitic diseases in 24.8% versus 15.3%, respectively.
21 ation of biologic agents in the treatment of vasculitic diseases may also provide important insights
22 related to the development of autoimmune and vasculitic diseases through unintended but detrimental b
23 esion formation and vascular damage in human vasculitic diseases.
24 atment follows ascertainment of the specific vasculitic disorder and the underlying cytochemical mech
25 ng CGRP inhibitors to patients with systemic vasculitic disorders and highlights the importance of fu
26                                              Vasculitic disorders often exhibit a strict age preferen
27 course of the illness, the patient developed vasculitic features and "rheumatoid-like" nodules.
28 re driven by genetic mutations, also exhibit vasculitic features and are associated with a high risk
29 ue-protective PD1/PD-L1 checkpoint unleashes vasculitic immunity and regulates the pathogenic remodel
30           Also, CCR6(+) T cells dominate the vasculitic infiltrates in patients with panarteritic gia
31 produced the chemokines CCL19 and CCL21, but vasculitic infiltrates were lacking.
32 dent memory T cells, needed to replenish the vasculitic infiltrates, depended on CD28 signaling.
33 pts for interleukin-12 p40 are absent in the vasculitic infiltrates.
34 ); SELENA-SLEDAI and/or BILAG neurologic and vasculitic involvement (on 2 indices: any new BILAG A do
35 by asthma, eosinophilia and granulomatous or vasculitic involvement of several organs.
36 rd SLE therapy and had renal, neurologic, or vasculitic involvement, elevated anti-dsDNA or BLyS leve
37 suggests that ANCAs may potentiate the early vasculitic lesion and promote tissue damage and recruitm
38 ng those organs in which the excision of the vasculitic lesion can be curative.
39 development of autoimmune disease, including vasculitic lesion formation and glomerulonephritis.
40 of eNOS in the initiation and progression of vasculitic lesion formation.
41 , the p.Met41Val variant was associated with vasculitic lesions (11 of 20 patients [55%]) with a mixe
42 ooth muscle cells, were sufficient to induce vasculitic lesions after adoptive transfer to recipient
43                                              Vasculitic lesions contain a diverse array of effector T
44 ssociated vasculitic neuropathy results from vasculitic lesions distributed diffusely throughout peri
45                             In the cutaneous vasculitic lesions from test patients, but not control s
46 transfer, corresponding to the occurrence of vasculitic lesions in mouse lungs.
47               IFN-gamma-producing T cells in vasculitic lesions of giant cell arteritis express sever
48 e cells to healthy recipient mice results in vasculitic lesions predominantly in postcapillary venule
49 ne complexes, such as peripheral neuropathy, vasculitic lesions, and hypocomplementemia.
50  cells, populate normal arteries, intramural vasculitic lesions, and the inflamed atheroma.
51             HCV was present in the cutaneous vasculitic lesions, most likely in complexes with IgM an
52  influx into the retina together with severe vasculitic lesions, retinal folding, and photoreceptor c
53 -Ig-treated animals were also protected from vasculitic lesions.
54 e could be induced by transfer of serum from vasculitic mice to untreated animals but not by transfer
55 onsensus recommendation on classification of vasculitic neuropathies and diagnosis/treatment of NSVN.
56                                          The vasculitic neuropathies are a diverse group of disorders
57 assification scheme can be used in which the vasculitic neuropathies are divided into two groups-nerv
58 ocal motor neuropathy with conduction block, vasculitic neuropathies, and motor neuron disease as par
59 ighlight recent developments in the field of vasculitic neuropathies.
60                                              Vasculitic neuropathy (multiple mononeuropathy) also has
61 pendent neuropathies (n = 1), and asymmetric vasculitic neuropathy (n = 1).
62 es, but less commonly appears as nonsystemic vasculitic neuropathy (NSVN).
63 e patients classified as having non-systemic vasculitic neuropathy have a systemic vasculitis present
64                           PURPOSE OF REVIEW: Vasculitic neuropathy is a heterogeneous disorder that u
65                                              Vasculitic neuropathy is caused by inflammatory destruct
66                                 Non-systemic vasculitic neuropathy is one of many localized vasculiti
67                 A new cohort of non-systemic vasculitic neuropathy patients was recently reported.
68                               MPA-associated vasculitic neuropathy results from vasculitic lesions di
69                                              Vasculitic neuropathy usually presents with painful mono
70 ticle reviews the literature on non-systemic vasculitic neuropathy, with emphasis on recent advances,
71 inical course and prognosis in patients with vasculitic neuropathy.
72  the mainstay of treatment for most forms of vasculitic neuropathy.
73 nd perpetuation of inflammatory processes in vasculitic neuropathy.
74  the diagnosis and follow-up of non-systemic vasculitic neuropathy.
75 f vascular and axonal damage in non-systemic vasculitic neuropathy.
76 lar damage in this patient is secondary to a vasculitic neuropathy.
77 temic lupus erythematosus or sarcoidosis), a vasculitic or granulomatous process can often be identif
78 ma typical, the clinical features during the vasculitic phase widely overlap with those of the other
79 y be helpful in predicting the extent of the vasculitic process.
80 nosis of CAA includes atherosclerosis, other vasculitic processes, connective tissue disorders, fistu
81 ten occur with comorbid neuroinflammatory or vasculitic processes.
82 renal and lung vasculitis; patients with non-vasculitic renal disease; or healthy controls.
83 eritoneal fibrosis, along with some atypical vasculitic symptomatology.
84 was defined as the time to the resurgence of vasculitic symptoms.
85 al infections can clinically mimic a primary vasculitic syndrome and can directly cause a vasculitis
86 t is even more pronounced in the age-related vasculitic syndrome giant cell arteritis.
87              Giant cell arteritis (GCA) is a vasculitic syndrome that preferentially affects medium a
88 ns - for example hepatitis B or C with known vasculitic syndromes - most of the purported links betwe
89 ble interest in the possibilities of primary vasculitic syndromes caused in some fashion by infection
90 ruses, particularly hepatitis C, and various vasculitic syndromes continues to grow.
91 alidation and testing of the VDI in specific vasculitic syndromes, and should facilitate the comparis
92  cardiac involvement vary with the different vasculitic syndromes.
93 ents were PD-L1(lo), whereas the majority of vasculitic T cells expressed PD-1, suggesting inefficien
94 l wall dendritic cells to differentiate into vasculitic T cells.
95  is a marked plasma cell response within the vasculitic tissue in KS, with unusual IgA production loc
96 ce of many Ig-producing B lymphocytes in the vasculitic tissue.